Axogen opened lower at $57.75, compared with its previous close of $58.63. In the last trading session, the stock traded between $53.87 and $58.35. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Axogen is now worth
$ 435.93
Giving a profit of
$ 335.93 (335.93%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 11 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-3.18 (-5.42%)
Day High
$58.35
Day Low
$53.87
Day Open
$57.75
Prev Close
$58.63
Volume
25,08,071
1W Return
8.12%
1M Return
49.41%
3M Return
14.38%
6M Return
35.94%
1Y Return
126.70%
Fundamentals
Market Cap ($ Mn)
3,312
PE Ratio
-
PB Ratio
10.77
PEG Ratio
-
ROE
-13.75%
ROCE
-4.37%
EPS (TTM)
$0.04
Investment Returns
1 Week
8.12%
1 Month
49.41%
3 Months
14.38%
6 Months
35.94%
9 Months
63.57%
Financials
Quarterly
All values in $ Mn
56.7
Jun 25
60.1
Sep 25
59.9
Dec 25
61.5
Mar 26
69.7
Jun 26
75.8
Sep 26
Updates
2Oct
Axogen completes BioCircuit acquisition, adds $34 million 2027 revenue
Axogen completed the acquisition of BioCircuit Technologies on October 1, 2026. BioCircuit expected to contribute $6 million to Q4 2026 revenue. Projected revenue contribution rises to $34 million for 2027. New revenue figures exclude prior guidance of at least 24% growth. Axogen maintains gross margin guidance of at least 73% for 2026.
1mo ago
10Sep
Axogen raises $208.7M to fund $200M BioCircuit acquisition
Axogen prices 4.91M shares at $42.50, raising ~$208.7M gross proceeds. Funds $200M cash acquisition of BioCircuit Technologies for sutureless nerve repair tech. Deal expected to boost revenue growth, EPS, and EBITDA margins in first year post-close. Transaction closing scheduled for Q4 2026; updated FY26/FY27 guidance to follow. Shares fell 10.54% to $45.46 following the announcement.
2mo ago
1Sep
Axogen to hold investor meetings at Morgan Stanley healthcare conference
Axogen management to hold one-on-one investor meetings on September 15, 2026. Event is the 24th Annual Morgan Stanley Global Healthcare Conference. Company specializes in peripheral nerve regeneration and repair solutions. Portfolio includes Avance nerve grafts and Axoguard nerve connectors.
2mo ago
26Aug
Truist Securities initiates Axogen coverage with Buy rating, $60 target
Truist Securities initiates coverage on Axogen (NASDAQ: AXGN). Analyst Ravi Misra assigns a Buy rating to the stock. Price target is set at $60. No operational or financial data disclosed in the note.
